NICE does not recommend Entyvio as a treatment for Crohn's Disease-Takeda

The National Institute for Health and Care Excellence (NICE) does not to recommend Entyvio (vedolizumab), from Takeda, as a treatment moderate to severe Crohn’s disease. The Appraisal Committee reviewed the submission from Takeda and decided that “the evidence for the drug is too uncertain” and that “the drug was not likely to represent good value for the NHS”. NICE commented that “Unfortunately the maker of Entyvio did not give the committee enough information to show how well it worked when compared to other treatments. We have to be sure that a drug is both effective and cost-effective before it can be recommended". NICE in its previous draft guidance has provisionally approved Entyvio as the first maintenance treatment for people with moderate to severe active ulcerative colitis.